Pancreas Registry and High Risk Registry

Plain-language summary

This registry study aims to follow individuals and families at high risk for pancreatic cancer. It includes people with a first-degree relative affected by pancreatic cancer, carriers of mutations such as BRCA1, BRCA2, PALB2, ATM, CDKN2A or STK11, those with Lynch syndrome, or people over 18 with pancreatic cysts of a certain size. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Icahn School of Medicine at Mount Sinai

Start date

3/1/2013

Estimated completion

1/1/2033

Countries

United States

Related genes

Locations

• New York, United States
• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* At least 1 first degree relative affected with Pancreatic Cancer
* Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer
* mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer
* Known mutation carrier for STK11 (Peutz Jeghers Syndrome)
* Lynch syndrome (HNPCC) + 1 family PDAC
* Known mutation carrier for Hereditary pancreatitis
* Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm

Exclusion Criteria:

* Patients who do not speak English or Spanish
* Refusal by patient
* Individuals under the age of 18 years